#ASCO24 update 🔔

In this modular phase 1 trial, the combination of fractionated chemotherapy with a radiopharmaceutical was evaluated in patients with #mCRPC .

Check out the abstract to learn more 👇

Abstract 5049, Poster 455

A new post hoc analysis of the ARASENS trial evaluated post-progression survival in patients with #mHSPC .

Visit Marc-Oliver Grimm at Poster 489 to learn more 👇

Abstract 5083, Poster 489

#ASCO24

New data from the ARAMIS trial will be presented at #ASCO24 .

Learn more about the association between PSA level and risk of radiological progression in patients with #nmCRPC from this follow-up analysis 👇

Abstract 5022, Poster 318

Bayer Oncology will be attending #ASCO24 🙌

Learn more about Bayer’s exciting pipeline and mission in precision oncology by visiting our medical booth (#17078).

More information can also be found on the Oncology Pipeline website 👇

#CancerResearch #PrecisionOncology ASCO

#RWE is increasingly recognized for its value and impact, bridging gaps in knowledge alongside evidence from #ClinicalTrials .

Explore further below 👇

Thank you A-Barzi & Pedro Uson Junior, MD for your contributions!

New data and collaborative patient management are key in shaping personalized treatment in #ProstateCancer .

Hear from PeerView‘s panel of experts, including Dr Karim Fizazi, Pedro C Barata, MD MSc FACP, Dr Kim N. Chi, and Dr Alicia Morgans.

Available for CME credit. Register below 👇

#MedEd

.GI CONNECT celebrates 10 years! 🎉

Bayer is proud to support programs that reach 54,000 healthcare professionals in 30 countries. Here’s to many more years!

Learn more: cor2ed.com/gi-connect/pro…

#MedEd #GICancer COR2ED

#AACR24 : Explore the preclinical results of a targeted radionuclide therapy in metastatic #ProstateCancer 👇

Abstract 6033, Poster Session

#CancerResearch AACR

#AACR24 : Learn preclinical results from a targeted radionuclide therapy in metastatic, castration-resistant prostate cancer ⬇️

Abstract ND09, Oral Presentation

#mCRPC #CancerResearch AACR

#AACR24 : discover preclinical results of a targeted alpha therapy and androgen receptor inhibitor in prostate cancer 👇

Abstract 688, Poster Session

#ProstateCancer #CancerResearch AACR

Bayer Oncology is a proud supporter of AACR’s Scientist Survivor Program.

Visit the Bayer Medical Booth (# 2927) for more information about clinical trials, patients and their personal perspectives or visit the link below 👇

#AACR24 #AACRSSP #PrecisionOncology

Bayer Oncology will be attending #AACR24 .

Learn more about Bayer’s mission in Precision Oncology and our Pipeline by visiting our Medical Booth (# 2927).

More information can also be found on the Oncology Pipeline website below.

#CancerResearch #PrecisionOncology AACR

#EAU24 : Bayer Oncology uncovers results from the Phase 3 ARASENS trial in Europe.

Find out more 👇

#ADT #mHSPC